MedTrace Logo

Eribulin and Lenvatinib in Advanced Solid Tumors

NCT02640508 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2024-05-09

Study results available
· View outcomes & findings →

Summary

The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.

Conditions

Interventions

DRUG

Eribulin

Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.

DRUG

Lenvatinib

Will be taken orally at 20-24 mg daily in each 21 day cycle.

Sponsors & Collaborators

  • Eisai Inc.

    collaborator INDUSTRY

  • Virginia G. Kaklamani

    lead OTHER

Principal Investigators

  • Virginia Kaklamani, MD · University of Texas Health Science Center San Antonio

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2020-11-24
Completion
2023-01-12

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02640508 on ClinicalTrials.gov